567 results on '"Renneville, Aline"'
Search Results
2. RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives
3. Therapy-related myelodysplastic syndromes in the genomics era
4. Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML
5. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.
6. Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML
7. CXCL8 secreted by immature granulocytes inhibits wildtype hematopoiesis in chronic myelomonocytic leukemia
8. Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia
9. Clonal Hematopoiesis in Patients With Cancer: How Much Should We Care?
10. Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors
11. Chronic myelomonocytic leukemia diagnosis and management
12. Targeting Heterochromatin Eliminates Malignant Stem Cells in Chronic Myelomonocytic Leukemia Through Reactivation of Retroelements and Innate Immune pathways
13. 1510 Multiomic functional biomarkers for cancer prediction and early detection
14. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
15. The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants
16. Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia
17. Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations
18. Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia
19. When monoclonal gammopathy‐associated chronic neutrophilic leukemia is a reactive process distinct from a clonal myeloproliferative neoplasm: Lessons from mistakes
20. Data from Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies
21. Supplementary Data from Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies
22. Supplementary Table S1 from Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies
23. Supplemental Table 3 Characteristics of patients with WM according to CXC4 mutation status from Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia
24. Supplemental Table 1 Gene expression profilling from Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia
25. Supplementary Table 1, Supplementary Figures 1-4 from TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia
26. List of pathways analyzed for GSEA from Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia
27. Comprehensive mutational profiling of core binding factor acute myeloid leukemia
28. Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion
29. Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group
30. Comparison of TP53 mutations screening by functional assay of separated allele in yeast and next-generation sequencing in myelodysplastic syndromes
31. EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression
32. Disease evolution and outcomes in familial AML with germline CEBPA mutations
33. Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?
34. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine
35. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders
36. MYD88 L265P mutation in Waldenstrom macroglobulinemia
37. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
38. Clonal architecture of chronic myelomonocytic leukemias
39. Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis
40. Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial
41. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes
42. Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia
43. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial
44. Use of thalidomide analogues in the treatment of haematological malignancies
45. Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML
46. Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis
47. Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers
48. 1-Year Data Analysis from a Cancer Center Molecular Tumor Board Dedicated to Clonal Hematopoiesis
49. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA
50. Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.